Design Therapeutics leads approach as four bio IPOs elevate $641M for...

The momentum in biotech IPOs continued this week as four more companies made their IPOs. According to the IPO research firm Renaissance Capital, IPO activity...

Subsequent-Technology Imaging Might Result in Change in Administration of Prostate Most...

Next-generation imaging can enable the detection of metastases that are otherwise undetectable with conventional imaging. This underscores a new technology and resource that,...

Comedy present proceeds to assist fund Alta. lady’s most cancers therapy

EDMONTON - A local family hopes comedy will be part of the...

Boundless Bio Appoints Shailaja Kasibhatla, Ph.D., as Vice President, Discovery and...

- Dr. Kasibhatla brings extensive expertise in drug development across multiple mechanisms of action and therapy modalities, as well as a thorough understanding...

AVEO Places Fotivda to the Check with BMS’ Opdivo in Kidney...

Today, AVEO Oncology announced It had entered into a collaboration and supply agreement for clinical trials Bristol Myers Squibb Fotivda in combination with the...

Sylvester Researchers Reveal New Hyperlink Between Weight problems, Chemerin and Kidney...

Newswise - Altered cellular energetics, a hallmark of cancer, has been linked to obesity. However, there was a lack of links between systemic...

Prostate Most cancers Therapy Market to Construct Extreme Income at Wholesome...

Prostate Cancer Treatment Market by Drug Type (Biological Therapy, Chemotherapy, Hormone Therapy,...

Anixa Biosciences Publicizes Issuance and Publication of European Patent for Ovarian...

SAN JOSE, California, March 12, 2021 / PRNewswire / - Anixa Biosciences, Inc. (NASDAQ: ANIX), a biotechnology company focused on the treatment and...

Bluebird Bio Reviews No Proof that LentiGlobin for Sickle Cell Causes...

Last month, Bluebird Bio stopped Phase 1/2 and Phase 3 trials of LentiGlobin gene therapy in sickle cell disease after a patient was diagnosed...

Recent Posts